ProfileGDS5678 / 1440211_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 49% 56% 49% 48% 55% 50% 48% 48% 47% 48% 49% 48% 47% 49% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2060949
GSM967853U87-EV human glioblastoma xenograft - Control 23.3943656
GSM967854U87-EV human glioblastoma xenograft - Control 33.1740849
GSM967855U87-EV human glioblastoma xenograft - Control 43.0879548
GSM967856U87-EV human glioblastoma xenograft - Control 53.3377655
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.29350
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.208948
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1400548
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1013647
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1293448
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1650149
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0948448
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1268747
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1618449